Figure 5.
Forest plot and pooled RR and 95% CI for subgroup DCR: “ICI combination therapy” versus “ICI monotherapy”. (a: DCR of 1st line; b: DCR of “≥2nd line”; c: DCR of anti-PD-1 therapy in control group; d: DCR of anti-PD-L1 therapy in control group; e: DCR of anti-CTLA4 therapy in control group; f: DCR of melanoma; g: DCR of gastric or esophagogastric cancer; h: DCR of head and neck squamous cell carcinoma) RR, risk ratios; CI, confidence intervals; DCR, objective response rate; ICI, immune checkpoint inhibitor.